TRACE
Trace a source
tape livemanual reviewONevidenceREQUIREDjson/trace.jsontracked horizons1D · 7D · 30D · 90Ddisclaimernot financial advicetape livemanual reviewONevidenceREQUIREDjson/trace.jsontracked horizons1D · 7D · 30D · 90Ddisclaimernot financial advice
publisheddirectional thesisLONGyoutubenot an explicit trade

LLY directional thesis

A GLP-1 maker re-rated as a longevity franchise, not a weight-loss fad: organ-wide benefits and a next-gen oral pill stretch the paying patient pool far past obesity for the class leader.

$930.36entry snapshot
pendingcurrent snapshot
— pendingsince mention
Well, I spend about half of my time in AI and half my time in longevity, right? I've written a few books there. I have a large venture fund investing tech, building companies in the space. And you're right, GLP-1, by the longevity health community, is considered really the very first longevity drug. And part of it is we know that if you are metabolically unhealthy, if you're carrying too much visceral fat, if you're carrying too much fat on your body, that shortens your life.
115:44claim_id mcl_4d49cb21090f6622dfopen evidence ↗
Classification directional thesis

Human-reviewed public claim.

Evidence span 115:44

Evidence URL, source timestamp, and excerpt are attached to this permanent claim page.

Correction path available

Creators or reviewers can request reclassification, context, or entity corrections without erasing the source record.

Machine-readable claim
{
  "version": "market-claims.v1",
  "claim": {
    "id": "mcl_4d49cb21090f6622df",
    "url": "/trace/claims/mcl_4d49cb21090f6622df",
    "status": "PUBLISHED",
    "claimType": "DIRECTIONAL_THESIS",
    "direction": "LONG",
    "claimText": "A GLP-1 maker re-rated as a longevity franchise, not a weight-loss fad: organ-wide benefits and a next-gen oral pill stretch the paying patient pool far past obesity for the class leader.",
    "confidence": 0.72,
    "expert": {
      "slug": "peterdiamandis",
      "displayName": "Peter H. Diamandis, MD",
      "kind": "PERSON",
      "status": "UNCLAIMED",
      "avatarUrl": "/api/avatars/2b149b43-6",
      "url": "/trace/experts/peterdiamandis",
      "claimed": false
    },
    "primaryEntity": {
      "kind": "ASSET",
      "assetClass": "EQUITY",
      "symbol": "LLY",
      "name": "LLY",
      "exchange": null,
      "confidence": 0.78
    },
    "evidence": {
      "evidenceUrl": "https://www.youtube.com/watch?v=BD7kXb50Np8&t=6944s",
      "sourceUrl": "https://youtube.com/watch?v=BD7kXb50Np8",
      "timecode": "115:44",
      "startMs": 6944000,
      "endMs": null,
      "excerpt": "Well, I spend about half of my time in AI and half my time in longevity, right? I've written a few books there. I have a large venture fund investing tech, building companies in the space. And you're right, GLP-1, by the longevity health community, is considered really the very first longevity drug. And part of it is we know that if you are metabolically unhealthy, if you're carrying too much visceral fat, if you're carrying too much fat on your body, that shortens your life."
    },
    "performance": {
      "entryPrice": 930.36,
      "currentPrice": null,
      "returnPct": null,
      "relativePct": null,
      "method": "PASTE_AUTHOR_PRICE"
    },
    "resolutionStatus": "OPEN",
    "ambiguityNotes": null,
    "horizon": null,
    "isExplicitTrade": false,
    "notFinancialAdvice": true,
    "disclaimer": "AISO tracks public statements, not verified portfolio positions. This is not financial advice."
  },
  "expert": {
    "slug": "peterdiamandis",
    "displayName": "Peter H. Diamandis, MD",
    "kind": "PERSON",
    "status": "UNCLAIMED",
    "avatarUrl": "/api/avatars/2b149b43-6",
    "url": "/trace/experts/peterdiamandis",
    "claimed": false
  },
  "source": {
    "platform": "YOUTUBE",
    "title": "The Case for Holidays, Artemis II Recap, Work vs Leisure, AI Backlash, Geopolitical Solutions",
    "sourceUrl": "https://youtube.com/watch?v=BD7kXb50Np8",
    "publishedAt": "2026-04-13T19:53:18.000Z"
  },
  "evidence": {
    "evidenceUrl": "https://www.youtube.com/watch?v=BD7kXb50Np8&t=6944s",
    "sourceUrl": "https://youtube.com/watch?v=BD7kXb50Np8",
    "timecode": "115:44",
    "startMs": 6944000,
    "endMs": null,
    "excerpt": "Well, I spend about half of my time in AI and half my time in longevity, right? I've written a few books there. I have a large venture fund investing tech, building companies in the space. And you're right, GLP-1, by the longevity health community, is considered really the very first longevity drug. And part of it is we know that if you are metabolically unhealthy, if you're carrying too much visceral fat, if you're carrying too much fat on your body, that shortens your life.",
    "quote": "Well, I spend about half of my time in AI and half my time in longevity, right? I've written a few books there. I have a large venture fund investing tech, building companies in the space. And you're right, GLP-1, by the longevity health community, is considered really the very first longevity drug. And part of it is we know that if you are metabolically unhealthy, if you're carrying too much visceral fat, if you're carrying too much fat on your body, that shortens your life.",
    "speaker": "Peter Diamandis"
  },
  "entities": [
    {
      "kind": "ASSET",
      "assetClass": "EQUITY",
      "symbol": "LLY",
      "name": "LLY",
      "exchange": null,
      "confidence": 0.78
    }
  ],
  "marketData": {
    "entry": {
      "price": 930.36,
      "currency": "USD",
      "observedAt": "2026-04-13T19:53:18.000Z",
      "method": "PASTE_AUTHOR_PRICE"
    },
    "current": null,
    "returnPct": null
  },
  "snapshots": [
    {
      "kind": "ENTRY",
      "symbol": "LLY",
      "assetClass": "EQUITY",
      "price": 930.36,
      "probability": null,
      "currency": "USD",
      "provider": "paste.trade",
      "providerSymbol": "xyz:LLY",
      "observedAt": "2026-04-13T19:53:18.000Z",
      "method": "PASTE_AUTHOR_PRICE",
      "returnPct": null,
      "relativePct": null
    }
  ]
}

AISO Market Calls classifies public statements from public sources. A classification such as long thesis, short thesis, or explicit call describes the content of the public statement and does not prove that the speaker actually entered, exited, or held a position. Market performance shown is calculated from public market data around the source publication or timestamp. It is not investment advice.